A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

NCT03104400 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1705

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: Adalimumab
DRUG: Upadacitinib
DRUG: Placebo to Upadacitinib
DRUG: Placebo to Adalimumab

Sponsor

AbbVie